Hydrocodone/paracetamol immediate release - Teva Pharmaceutical

Drug Profile

Hydrocodone/paracetamol immediate release - Teva Pharmaceutical

Alternative Names: Acetaminophen/hydrocodone bitartarate - Teva Pharmaceutical; TV-46763

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 01 May 2016 Teva Pharmaceutical completes a phase III trial in Pain (Abuse-resistant) in USA (NCT02487108)
  • 31 Aug 2015 Phase-III clinical trials in Pain (Abuse-resistant) in USA (PO)
  • 08 Jul 2015 Teva Pharmaceutical plans a phase III trial in Pain (In adults, In the elderly) in USA (NCT02487108)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top